Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative ...

Turkish and European researchers will collaborate on the treatment of brain diseases and patient care through new projects ...

Recovery.com, a global platform that connects patients, loved ones, and providers to mental health and addiction treatment options, has released its first-ever State of Recovery report. Based on ...

Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Several neuropsychiatric disorders such as attention deficit-hyperactivity disorder (ADHD), autism spectrum disorder (ASD), as well as neurological diseases such as spinocerebellar ataxia type 3 (SCA3 ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Of the 15 neurological disorders listed, some of which have symptoms of progeria, six—spinocerebellar ataxia with axonal neuropathy-1, Huntington's disease, Alzheimer's disease, Parkinson's ...

Troriluzole: Troriluzole is a novel glutamate modulator currently in Phase 3 development for Spinocerebellar ataxia and obsessive-compulsive disorder. A new drug application was submitted to US ...

It is with heavy hearts the family of Martin Albert Hoffart announce his passing on January 10, 2025. Martin was born in ...

Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA). According to GlobalData, Phase II drugs for Spinocerebellar Ataxia (SCA) have a 29% ...